ANNETT WILLIAM 4
4 · OncoCyte Corp · Filed Jun 1, 2018
Insider Transaction Report
Form 4
ANNETT WILLIAM
DirectorPresident and CEO
Transactions
- Award
Option to Purchase Common Stock
2018-05-23+180,000→ 180,000 totalExercise: $2.35Exp: 2028-05-22→ Common Stock (180,000 underlying)
Holdings
- 5,000
Option to Purchase Common Stock
Exercise: $2.20Exp: 2025-01-08→ Common Stock (5,000 underlying) - 250,000
Option to Purchase Common Stock
Exercise: $4.70Exp: 2027-02-16→ Common Stock (225,000 underlying) - 250,000
Option to Purchase Common Stock
Exercise: $3.06Exp: 2026-02-15→ Common Stock (250,000 underlying) - 605,000
Option to Purchase Common Stock
Exercise: $2.20Exp: 2025-06-15→ Common Stock (605,000 underlying)
Footnotes (5)
- [F1]One quarter of the options shall vest upon completion of the clinical utility study for OncoCyte's DetermaVu product candidate and OncoCyte has received a publication date for a full article describing those results, and the balance shall vest upon obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
- [F2]One quarter of the options vested on February 16, 2018, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- [F3]One quarter of the options vested on February 15, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- [F4]One quarter of the options vested on June 15, 2016, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment.
- [F5]Became exercisable in two equal installments based upon continued service on the board of directors from the date of grant on January 9, 2015.